BR112016027671A2 - ?anticorpos, composição e kit? - Google Patents
?anticorpos, composição e kit?Info
- Publication number
- BR112016027671A2 BR112016027671A2 BR112016027671-0A BR112016027671A BR112016027671A2 BR 112016027671 A2 BR112016027671 A2 BR 112016027671A2 BR 112016027671 A BR112016027671 A BR 112016027671A BR 112016027671 A2 BR112016027671 A2 BR 112016027671A2
- Authority
- BR
- Brazil
- Prior art keywords
- herv
- composition
- antibody
- antibodies
- kit
- Prior art date
Links
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 230000000798 anti-retroviral effect Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 102100034349 Integrase Human genes 0.000 abstract 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 abstract 1
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 108010037253 syncytin Proteins 0.000 abstract 1
- 241001430294 unidentified retrovirus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Abstract
a invenção refere-se a um anticorpo, um fragmento ou um derivado do mesmo, para uso como uma droga antirretroviral de direcionamento de um vírus pertencente aos retrovírus endógenos humanos tipo w (herv-w), em que o dito anticorpo, fragmento ou derivado do mesmo é direcionado contra proteína do envelope de herv-w (herv-w env). a invenção também se refere a uma composição que compreende o dito anticorpo e uma droga inibitória de transcriptase reversa, para uso como uma droga antirretroviral de direcionamento de um vírus pertencente ao herv-w.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14305806.3 | 2014-05-28 | ||
| EP14305806.3A EP2949342A1 (en) | 2014-05-28 | 2014-05-28 | Antiretroviral drug targeting human endogenous retrovirus |
| PCT/EP2015/061691 WO2015181226A1 (en) | 2014-05-28 | 2015-05-27 | Antiretroviral drug targeting human endogenous retrovirus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112016027671A2 true BR112016027671A2 (pt) | 2018-01-30 |
| BR112016027671B1 BR112016027671B1 (pt) | 2023-11-21 |
| BR112016027671B8 BR112016027671B8 (pt) | 2024-01-09 |
Family
ID=50976559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016027671A BR112016027671B8 (pt) | 2014-05-28 | 2015-05-27 | Uso de um anticorpo |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20170101461A1 (pt) |
| EP (2) | EP2949342A1 (pt) |
| JP (1) | JP2017519815A (pt) |
| KR (1) | KR20170012376A (pt) |
| CN (2) | CN114276444A (pt) |
| AR (1) | AR100642A1 (pt) |
| AU (1) | AU2015265936B2 (pt) |
| BR (1) | BR112016027671B8 (pt) |
| CA (1) | CA2949884C (pt) |
| DK (1) | DK3148582T3 (pt) |
| EA (1) | EA034612B1 (pt) |
| EC (1) | ECSP16091728A (pt) |
| ES (1) | ES2752131T3 (pt) |
| HU (1) | HUE046187T2 (pt) |
| IL (1) | IL249040B (pt) |
| MX (1) | MX2016015560A (pt) |
| PL (1) | PL3148582T3 (pt) |
| PT (1) | PT3148582T (pt) |
| RU (1) | RU2689326C1 (pt) |
| SG (1) | SG11201609886SA (pt) |
| TW (1) | TW201625679A (pt) |
| UA (1) | UA120274C2 (pt) |
| WO (1) | WO2015181226A1 (pt) |
| ZA (1) | ZA201608050B (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018028538A (ja) * | 2016-08-12 | 2018-02-22 | 公立大学法人名古屋市立大学 | 統合失調症とその関連疾患の診断用マーカー及びその使用 |
| WO2019201908A1 (en) | 2018-04-17 | 2019-10-24 | Geneuro Sa | Method for the detection of the soluble hydrophilic oligomeric form of herv-w envelope protein |
| EP3916015A1 (en) * | 2020-05-28 | 2021-12-01 | Geneuro SA | Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0893691A1 (en) * | 1997-07-23 | 1999-01-27 | Mach, Bernard François, Prof. | Methods for diagnosis and therapy of autoimmunedisease, such as insulin dependent diabetes mellitus, involving retroviral superantigens |
| FR2791140B1 (fr) | 1999-03-19 | 2002-03-22 | Bio Merieux | Procede de detection d'une activite superantigenique dans un echantillon et composition therapeutique ou prophylactique |
| EP2266396A3 (en) * | 2001-09-24 | 2011-06-15 | Sangamo BioSciences, Inc. | Modulation of stem cells using zinc finger proteins |
| FR2865403B1 (fr) * | 2004-01-23 | 2009-06-12 | Biomerieux Sa | Composition pour le traitement d'une pathologie associee a la msrv/herv-w |
| FR2912314B1 (fr) * | 2007-02-09 | 2012-08-03 | Geneuro Sa | Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w. |
| SI3211005T1 (sl) * | 2008-07-08 | 2021-06-30 | Geneuro Sa | Terapevtska uporaba specifičnega liganda pri boleznih, povezanih z MSRV |
| US20120321637A1 (en) * | 2011-06-20 | 2012-12-20 | The Board Of Regents Of The University Of Texas System | Combination cancer therapy with herv inhibition |
| UA119032C2 (uk) * | 2012-10-02 | 2019-04-25 | Женеро Са | Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w |
-
2014
- 2014-05-28 EP EP14305806.3A patent/EP2949342A1/en not_active Withdrawn
-
2015
- 2015-05-27 CN CN202111589814.XA patent/CN114276444A/zh active Pending
- 2015-05-27 ES ES15725326T patent/ES2752131T3/es active Active
- 2015-05-27 DK DK15725326T patent/DK3148582T3/da active
- 2015-05-27 EA EA201692471A patent/EA034612B1/ru not_active IP Right Cessation
- 2015-05-27 CA CA2949884A patent/CA2949884C/en active Active
- 2015-05-27 RU RU2016151471A patent/RU2689326C1/ru active
- 2015-05-27 US US15/314,017 patent/US20170101461A1/en not_active Abandoned
- 2015-05-27 MX MX2016015560A patent/MX2016015560A/es active IP Right Grant
- 2015-05-27 UA UAA201613240A patent/UA120274C2/uk unknown
- 2015-05-27 BR BR112016027671A patent/BR112016027671B8/pt active Search and Examination
- 2015-05-27 EP EP15725326.1A patent/EP3148582B1/en active Active
- 2015-05-27 WO PCT/EP2015/061691 patent/WO2015181226A1/en active Application Filing
- 2015-05-27 HU HUE15725326A patent/HUE046187T2/hu unknown
- 2015-05-27 CN CN201580027652.7A patent/CN106536550A/zh active Pending
- 2015-05-27 JP JP2017514954A patent/JP2017519815A/ja active Pending
- 2015-05-27 KR KR1020167035895A patent/KR20170012376A/ko unknown
- 2015-05-27 SG SG11201609886SA patent/SG11201609886SA/en unknown
- 2015-05-27 PT PT157253261T patent/PT3148582T/pt unknown
- 2015-05-27 PL PL15725326T patent/PL3148582T3/pl unknown
- 2015-05-27 AU AU2015265936A patent/AU2015265936B2/en active Active
- 2015-05-28 AR ARP150101680A patent/AR100642A1/es unknown
- 2015-05-28 TW TW104117097A patent/TW201625679A/zh unknown
-
2016
- 2016-11-17 IL IL249040A patent/IL249040B/en active IP Right Grant
- 2016-11-21 ZA ZA2016/08050A patent/ZA201608050B/en unknown
- 2016-11-30 EC ECIEPI201691728A patent/ECSP16091728A/es unknown
-
2019
- 2019-03-22 US US16/362,193 patent/US10894820B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016003191A1 (es) | Polipéptidos receptores formulados y métodos relacionados | |
| BR112020002012A8 (pt) | Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39 | |
| BR112017010088A2 (pt) | polinucleotídeo modulatório, pré-micro-rna artificial, vírus recombinante de aav, composição compreendendo o plasmídeo ou vetor, kit compreendendo o referido plasmídeo ou vetor e uso do mesmo | |
| CL2018003135A1 (es) | Derivados aromáticos de sulfonamida. | |
| BR112016020199A2 (pt) | Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| BR112017002370A2 (pt) | indóis para uso na infecção pelo vírus da gripe | |
| CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
| BR112016017351A2 (pt) | Enxerto de stent pararenal e de arco torácico e métodos para uso | |
| BR112016030968A2 (pt) | análogos de pridopidina, preparação e uso destes | |
| BR112017000671A2 (pt) | moléculas com especificidade para cd79 e cd22 | |
| CR20160502A (es) | Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso | |
| BR112018071466A2 (pt) | novos peptídeos de ligação a cd1d imunogênicos | |
| BR112016024494A8 (pt) | análogo de peptídeo e seu uso | |
| CL2016001973A1 (es) | Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza. | |
| BR112019012796A2 (pt) | proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas | |
| BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
| CO2018005755A2 (es) | Mezcla hemostática de fibras cortas y largas basadas en celulosa | |
| BR112017002060A2 (pt) | novo uso | |
| CO2017000558A2 (es) | Variantes de proteínas de unión al factor h | |
| DOP2016000336A (es) | Derivados de isoindolina para uso en el tratamiento de una infeccion viral | |
| BR112016017046A2 (pt) | Anticorpos contra glicoproteína f de vírus hendra e nipah | |
| UY36221A (es) | Derivados de isoindolinona | |
| BR112017004140A2 (pt) | sondas para imageamento de proteína de huntingtina | |
| UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
| DK3292105T3 (da) | Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/05/2015, OBSERVADAS AS CONDICOES LEGAIS |
|
| B09W | Correction of the decision to grant [chapter 9.1.4 patent gazette] |
Free format text: RETIFICA-SE O DEFERIMENTO NOTIFICADO NA RPI NO 2753 DE 10/10/2023. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE A RPI 2759 DE 21/11/2023, QUANTO AO DESENHO. |